Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations · 23.5M shares · +81%/yr ↑ shares · EDGAR filings ↗
Grade
D44Clinical/early-stage biotech — neuro-immunology clinical, well-funded.
Strengths
- Liquidity — current ratio 8.5 (75th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Net lossNet loss (net margin -267.1%)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +81%/yr over 3y (dilution)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Notable holderHeld by 3 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, CITADEL ADVISORS LLC (as of 2026-03-31)
- Revenue declineRevenue -93.7% YoY
- AccumulatingInstitutional holders rose 4→5 QoQ (2025-12-31→2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-283.9%
Net margin
-267.1%
Return on equity
-49.3%
Return on assets
-42.5%
Revenue growth (QoQ)
-93.7%
Current ratio
8.5×
Tangible book value
$43M
Cash & investments
$47M
Stock comp / revenue
54.0%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-08-18 | GOLDSTEIN DOV A MD | Option exercise | 18K | $1.09 |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-25 | Shareholder vote | filing ↗ |
| 2026-05-12 | ResultsOtherExhibits | filing ↗ |
| 2026-05-12 | Material agreementExhibits | filing ↗ |
| 2026-04-02 | Exec/director changeExhibits | filing ↗ |
| 2026-03-16 | ResultsExhibits | filing ↗ |
| 2026-01-30 | Material agreement3.02Reg FDOtherExhibits | filing ↗ |
| 2026-01-20 | Other | filing ↗ |
| 2026-01-08 | Other | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-25 | 2026-06-25 | 0001193125-26-282989 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001193125-26-218201 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001193125-26-218282 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001193125-26-218198 ↗ |
| 8-K | 2026-04-02 | 2026-03-29 | 0001193125-26-139094 ↗ |
| 8-K | 2026-03-16 | 2026-03-16 | 0001193125-26-107276 ↗ |
| 10-K | 2026-03-16 | 2025-12-31 | 0001193125-26-107281 ↗ |
| 8-K | 2026-01-30 | 2026-01-29 | 0001193125-26-030531 ↗ |
| 8-K | 2026-01-20 | 2026-01-20 | 0001193125-26-016017 ↗ |
| 8-K | 2026-01-08 | 2026-01-08 | 0001193125-26-007042 ↗ |
| 8-K | 2025-12-17 | 2025-12-16 | 0001193125-25-321737 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001193125-25-276058 ↗ |